- Home
- SLGN vs DNTH Comparison
SLGN vs DNTH Comparison
Compare SLGN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGN | DNTH |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.5B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SLGN | DNTH |
|---|---|---|
| Price | $44.34 | $95.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $52.78 | ★ $121.00 |
| AVG Volume (30 Days) | 903.5K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 4.65 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $4,489,927,000.00 | $2,036,000.00 |
| Revenue This Year | $4.99 | N/A |
| Revenue Next Year | $2.20 | $29.48 |
| P/E Ratio | $73.38 | ★ N/A |
| Revenue Growth | ★ 0.92 | N/A |
| 52 Week Low | $35.68 | $18.08 |
| 52 Week High | $56.85 | $102.33 |
Technical Indicators
Market Signals| Indicator | SLGN | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 61.65 | 61.02 |
| Support Level | $36.81 | $79.27 |
| Resistance Level | $45.20 | $98.70 |
| Average True Range (ATR) | 1.40 | 5.37 |
| MACD | -0.17 | 0.93 |
| Stochastic Oscillator | 59.77 | 76.88 |
Price Performance
Historical ComparisonAbout SLGN Silgan Holdings Inc.
Silgan Holdings Inc is a manufacturer of sustainable rigid packaging solutions for the world's essential consumer goods products. Its products include: dispensing and specialty closures for fragrance and beauty, food, beverage, personal and health care, home care and lawn and garden products; steel and aluminum containers for pet and human food and general line products; and custom designed plastic containers for pet and human food, consumer health and pharmaceutical, personal care, home care, lawn and garden and automotive products.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.